Back to funds
View filing
Merck & Co., Inc.
institutionalUpdated 34 days agoManaged by Merck & Co., Inc. • Latest filing Q2 2026
Portfolio value
$526.4M
Q2 2026
Filings
7
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
7.1%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 7 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q4 2024 | $258M |
| Q1 2025 | $164.3M |
| Q2 2025 | $215.6M |
| Q3 2025 | $228M |
| Q4 2025 | $276.3M |
| Q1 2026 | $349.4M |
| Q2 2026 | $526.4M |
Top holdings
13 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | P PR PERSONALIS INC | $188.2M | 14.04M | 35.75% | — |
| 2 | M MRNA MODERNA INC | $161.6M | 2.31M | 30.71% | — |
| 3 | K KYMR KYMERA THERAPEUTICS INC | $88.5M | 772.2K | 16.82% | — |
| 4 | A AKTS AKTIS ONCOLOGY INC | $30.7M | 952.8K | 5.83% | — |
| 5 | E EIKN EIKON THERAPEUTICS INC | $21.7M | 1.67M | 4.13% | — |
| 6 | T TRDA ENTRADA THERAPEUTICS INC | $12.8M | 1.74M | 2.43% | — |
| 7 | ? N/A SUTRO BIOPHARMA INC | $9M | 272.4K | 1.72% | — |
| 8 | A ALEC ALECTOR INC | $7.1M | 3.55M | 1.35% | — |
| 9 | E EVAX EVAXION BIOTECH A/S | $3.8M | 1.21M | 0.71% | — |
| 10 | V VRDN VIRIDIAN THERAPEUTICS INC | $1.7M | 93.4K | 0.33% | — |
| 11 | ? N/A XILIO THERAPEUTICS INC | $1M | 106.0K | 0.19% | — |
| 12 | ? N/A TUHURA BIOSCIENCES INC | $46K | 19.4K | 0.01% | — |
| 13 | N NEUP NEUPHORIA THERAPEUTICS INC | $44K | 10.0K | 0.01% | — |